Serina Therapeutics (SER) Change in Account Payables (2018 - 2025)

Serina Therapeutics has reported Change in Account Payables for 8 years, with the latest figure at -$811000.0 in Q4 2025.

• Quarterly Change in Account Payables rose 14.54% year-over-year to -$811000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.2 million (up 172.07% YoY) and the FY2025 annual result came in at $1.2 million, up 172.07% from the prior year.
• Change in Account Payables eased to -$811000.0 in Q4 2025 per SER's latest filing, from $1.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $1.2 million in Q3 2023 and troughed at -$1.4 million in Q2 2024.
• A 5-year average of -$109722.2 and a median of -$217000.0 in 2021 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables soared 473.94% in 2023, then tumbled 630.0% in 2024.
• Over 5 years, Change in Account Payables stood at -$310000.0 in 2021, then dropped by 6.45% to -$330000.0 in 2022, then jumped by 60.61% to -$130000.0 in 2023, then sank by 630.0% to -$949000.0 in 2024, then grew by 14.54% to -$811000.0 in 2025.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$811000.0, $1.0 million, and $522000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.